Researchers in UT Pharmacy's Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs have earned a bevy of national and international awards for their work in pharmaceutical drug delivery and 3D printing personalized medicines.
Pharmacy schools across the country completed their 2022 Phase I and Phase II residency matches for new or upcoming graduates of their Doctor of Pharmacy (Pharm.D.) programs. The University of Texas at Austin College of Pharmacy placed in the top ten of all pharmacy schools in the nation, and number one in Texas.
Dr. Mo Maniruzzaman's Pharmaceutical Engineering and 3D Printing Labs have received a federal grant from the United States Agency for International Development (USAID) to develop personalized 3D printed non-hormonal intrauterine devices (IUDs). The project’s goal is to increase global access to long-term and effective contraception while minimizing some of its most debilitating side effects.
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.
The college's Pharmaceutical Engineering and 3D Printing (PharmE3D) labs, led by Assistant Professor in Molecular Pharmaceutics and Drug Delivery Mohammed (Mo) Maniruzzaman, Ph.D., has recently earned several national and international awards and scholarships for outstanding research contributions to the field of pharmaceutical science and technology.
Student pharmacist Johana Suh earned an undergraduate fellowship award for research on 3D bioprinted modeling of the neurodegenerative disease NPC-1, or Niemann-Pick disease type C1. Suh is a second-year Doctor of Pharmacy candidate in the UT College of Pharmacy, and serves as an undergraduate researcher in the Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs led by Mo Maniruzzaman, Ph.D.
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.